gefitinib has been researched along with oridonin in 1 studies
| Studies (gefitinib) | Trials (gefitinib) | Recent Studies (post-2010) (gefitinib) | Studies (oridonin) | Trials (oridonin) | Recent Studies (post-2010) (oridonin) |
|---|---|---|---|---|---|
| 5,231 | 566 | 2,919 | 465 | 0 | 349 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cai, F; Cao, W; Duan, C; Fan, C; He, Z; Huang, Q; Liu, Y; Wang, J; Wang, X; Xiao, X; Zhang, L | 1 |
1 other study(ies) available for gefitinib and oridonin
| Article | Year |
|---|---|
Oridonin inhibits gefitinib-resistant lung cancer cells by suppressing EGFR/ERK/MMP-12 and CIP2A/Akt signaling pathways.
Topics: A549 Cells; Animals; Autoantigens; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Cell Survival; Diterpenes, Kaurane; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; MAP Kinase Signaling System; Matrix Metalloproteinase 12; Membrane Proteins; Mice; Phosphorylation; Quinazolines; Xenograft Model Antitumor Assays | 2016 |